Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
Z Gastroenterol
; 43(3): 267-73, 2005 Mar.
Article
en En
| MEDLINE
| ID: mdl-15765299
ABSTRACT
BACKGROUND:
The tyrosine kinase inhibitor imatinib has been introduced into the treatment of gastrointestinal stromal tumors (GIST). Here we report our results of prolonged treatment in comparison to a similar group of GIST patients who had died before imatinib became available.METHODS:
Fourteen patients with recurrent or metastatic GIST were treated with imatinib. Clinical data and tumor samples of ten patients from the pre-imatinib era were available for comparison. Comparative genomic hybridisation (CGH) was performed on tumors to identify changes that may predict response to treatment.RESULTS:
Fourteen patients were treated, mean treatment time 22.3 months (1 non-response, 2 progression after initial response, 2 stable diseases, 8 partial responses, 1 complete response). Adverse side effects were mild in general. Survival was higher in the treated group (41.1 months vs. 34.8 months in the historical group). Eleven treated patients are alive. CGH analysis showed comparable numbers of chromosomal aberations in both groups.CONCLUSION:
Prolonged treatment with imatinib is safe and effective in patients with recurrent or metastatic GIST.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Piperazinas
/
Pirimidinas
/
Tumores del Estroma Gastrointestinal
/
Inhibidores de Proteínas Quinasas
/
Antineoplásicos
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Z Gastroenterol
Año:
2005
Tipo del documento:
Article
País de afiliación:
Alemania